Commercial Credit Report for NPT Co Ltd

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for NPT Co Ltd is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	NPT Co Ltd

Phone: +81 364557150p:+81 364557150	KOTO-KU, TKY 135-0063 Japan	Ticker: 311A311A

Business Summary

NPT Co Ltd is a Japan-based company engaged in the clinical development of novel drugs and therapies for personalized medicine. The Company operates through the Pharmaceutical Development segment. The Company specializes in oncology, develops modalities using regenerative medicine technology for cancer, conducts clinical trials under the approval of the Pharmaceuticals and Medical Devices Agency, obtains approval to manufacture and market regenerative medicine products, and then works to sell them in the market. The modality to be developed is the Personalized Antigen Presenting Cell Vaccine (PAPC vaccine). The PAPC vaccine is a cancer immuno-cell therapy in which mutant peptides derived from a genetic mutation called neo-antigen peptide expressed in the patient's cancer cells are loaded onto antigen-presenting cells obtained from the same patient, which are then returned to the patient's body. The Company is developing a PAPC vaccine as a modality for patients with esophageal cancer.

(Source: N-30D)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
10/31/2024	10/31/2024	-	-	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research

General Information

Number of Employees:	7	(As of 10/31/2024)
Outstanding Shares:	5,611,300	(As of 1/30/2025)
Stock Exchange:	TYO
Fax Number:	+81 364557035

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN